Pill versions of the obesity drugs currently administered as injections are nearing availability. We examine the science behind these pills adn whether they could offer a more affordable and accessible option to the existing injections.
AYESHA RASCOE, HOST: Drugs like Wegovy and Ozempic have become increasingly popular options for millions seeking a healthier weight. Tho, these drugs, given as weekly injections, aren’t suitable for everyone or every budget.This is why experimental pills with similar effects are generating notable interest. A wegovy-style pill is anticipated to receive Food and Drug Administration approval by year’s end. NPR pharmaceuticals correspondent Sydney Lupkin joins us to discuss this possibility. Welcome, Sydney.
SYDNEY LUPKIN, BYLINE: Thanks for having me.
RASCOE: Why haven’t pill versions of these drugs been available until now? It seems like a desirable option for many.
LUPKIN: It’s a valid question. There is a pill, Rybelsus, but it’s currently only approved for Type 2 diabetes. It’s manufactured by Novo Nordisk, the same company behind Ozempic for Type 2 diabetes and Wegovy for obesity. However, it contains a lower dose of the active ingredient – semaglutide – shared by the injectable drugs. The new pill would deliver a higher dose specifically for obesity patients, and studies indicate its effectiveness is comparable to Wegovy’s.Tracy Zvenyach, director of policy strategy and alliances at the nonprofit obesity Action Coalition, explains the importance of more options.
TRACY ZVENYACH: The obesity community has long lacked treatment options. New innovations and treatments are greatly needed.